Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Akcea Therapeutics, Inc.

https://akceatx.com/

Latest From Akcea Therapeutics, Inc.

J.P. Morgan Day 3: Preparing For The Future, Whatever That Holds

Daily round-up from the virtual J.P. Morgan Healthcare Conference: Teva promises growth is coming; Relay joins Roche in the KRAS race; UCB embraces the digital age; Agios and Ionis prepare for commercial battles. 

Business Strategies Companies

J.P. Morgan Day 3: Preparing For The Future, Whatever That Holds

Daily round-up from the virtual J.P. Morgan Healthcare Conference: Teva promises growth is coming; Relay joins Roche in the KRAS race; UCB embraces the digital age; Agios and Ionis prepare for commercial battles. 

Business Strategies Companies

Ionis, AstraZeneca To Use Real-World Data To Accelerate RNA-Targeting Cholesterol Drug

Early data presented at the American Heart Association showed strong PCSK9 and LDL cholesterol lowering for ION449; AstraZeneca plans rapid development under an RWE-based FDA pilot program.

Research & Development Analysis

Will Aducanumab Join List Of Drugs Approved By US FDA Over Advisory Committee Opposition?

A look at drugs the agency approved despite an advisory committee vote not to do so and how they compare to Biogen’s Alzheimer’s disease drug aducanumab.

Advisory Committees Drug Review
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Antisense, Oligonucleotides
UsernamePublicRestriction

Register